Cargando…

Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy

HIV and SIV infection dynamics are commonly investigated by measuring plasma viral loads. However, this total viral load value represents the sum of many individual infection events, which are difficult to independently track using conventional sequencing approaches. To overcome this challenge, we g...

Descripción completa

Detalles Bibliográficos
Autores principales: Fennessey, Christine M., Pinkevych, Mykola, Immonen, Taina T., Reynaldi, Arnold, Venturi, Vanessa, Nadella, Priyanka, Reid, Carolyn, Newman, Laura, Lipkey, Leslie, Oswald, Kelli, Bosche, William J., Trivett, Matthew T., Ohlen, Claes, Ott, David E., Estes, Jacob D., Del Prete, Gregory Q., Lifson, Jeffrey D., Davenport, Miles P., Keele, Brandon F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433785/
https://www.ncbi.nlm.nih.gov/pubmed/28472156
http://dx.doi.org/10.1371/journal.ppat.1006359
_version_ 1783236922615791616
author Fennessey, Christine M.
Pinkevych, Mykola
Immonen, Taina T.
Reynaldi, Arnold
Venturi, Vanessa
Nadella, Priyanka
Reid, Carolyn
Newman, Laura
Lipkey, Leslie
Oswald, Kelli
Bosche, William J.
Trivett, Matthew T.
Ohlen, Claes
Ott, David E.
Estes, Jacob D.
Del Prete, Gregory Q.
Lifson, Jeffrey D.
Davenport, Miles P.
Keele, Brandon F.
author_facet Fennessey, Christine M.
Pinkevych, Mykola
Immonen, Taina T.
Reynaldi, Arnold
Venturi, Vanessa
Nadella, Priyanka
Reid, Carolyn
Newman, Laura
Lipkey, Leslie
Oswald, Kelli
Bosche, William J.
Trivett, Matthew T.
Ohlen, Claes
Ott, David E.
Estes, Jacob D.
Del Prete, Gregory Q.
Lifson, Jeffrey D.
Davenport, Miles P.
Keele, Brandon F.
author_sort Fennessey, Christine M.
collection PubMed
description HIV and SIV infection dynamics are commonly investigated by measuring plasma viral loads. However, this total viral load value represents the sum of many individual infection events, which are difficult to independently track using conventional sequencing approaches. To overcome this challenge, we generated a genetically tagged virus stock (SIVmac239M) with a 34-base genetic barcode inserted between the vpx and vpr accessory genes of the infectious molecular clone SIVmac239. Next-generation sequencing of the virus stock identified at least 9,336 individual barcodes, or clonotypes, with an average genetic distance of 7 bases between any two barcodes. In vitro infection of rhesus CD4+ T cells and in vivo infection of rhesus macaques revealed levels of viral replication of SIVmac239M comparable to parental SIVmac239. After intravenous inoculation of 2.2x10(5) infectious units of SIVmac239M, an average of 1,247 barcodes were identified during acute infection in 26 infected rhesus macaques. Of the barcodes identified in the stock, at least 85.6% actively replicated in at least one animal, and on average each barcode was found in 5 monkeys. Four infected animals were treated with combination antiretroviral therapy (cART) for 82 days starting on day 6 post-infection (study 1). Plasma viremia was reduced from >10(6) to <15 vRNA copies/mL by the time treatment was interrupted. Virus rapidly rebounded following treatment interruption and between 87 and 136 distinct clonotypes were detected in plasma at peak rebound viremia. This study confirmed that SIVmac239M viremia could be successfully curtailed with cART, and that upon cART discontinuation, rebounding viral variants could be identified and quantified. An additional 6 animals infected with SIVmac239M were treated with cART beginning on day 4 post-infection for 305, 374, or 482 days (study 2). Upon treatment interruption, between 4 and 8 distinct viral clonotypes were detected in each animal at peak rebound viremia. The relative proportions of the rebounding viral clonotypes, spanning a range of 5 logs, were largely preserved over time for each animal. The viral growth rate during recrudescence and the relative abundance of each rebounding clonotype were used to estimate the average frequency of reactivation per animal. Using these parameters, reactivation frequencies were calculated and ranged from 0.33–0.70 events per day, likely representing reactivation from long-lived latently infected cells. The use of SIVmac239M therefore provides a powerful tool to investigate SIV latency and the frequency of viral reactivation after treatment interruption.
format Online
Article
Text
id pubmed-5433785
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-54337852017-05-26 Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy Fennessey, Christine M. Pinkevych, Mykola Immonen, Taina T. Reynaldi, Arnold Venturi, Vanessa Nadella, Priyanka Reid, Carolyn Newman, Laura Lipkey, Leslie Oswald, Kelli Bosche, William J. Trivett, Matthew T. Ohlen, Claes Ott, David E. Estes, Jacob D. Del Prete, Gregory Q. Lifson, Jeffrey D. Davenport, Miles P. Keele, Brandon F. PLoS Pathog Research Article HIV and SIV infection dynamics are commonly investigated by measuring plasma viral loads. However, this total viral load value represents the sum of many individual infection events, which are difficult to independently track using conventional sequencing approaches. To overcome this challenge, we generated a genetically tagged virus stock (SIVmac239M) with a 34-base genetic barcode inserted between the vpx and vpr accessory genes of the infectious molecular clone SIVmac239. Next-generation sequencing of the virus stock identified at least 9,336 individual barcodes, or clonotypes, with an average genetic distance of 7 bases between any two barcodes. In vitro infection of rhesus CD4+ T cells and in vivo infection of rhesus macaques revealed levels of viral replication of SIVmac239M comparable to parental SIVmac239. After intravenous inoculation of 2.2x10(5) infectious units of SIVmac239M, an average of 1,247 barcodes were identified during acute infection in 26 infected rhesus macaques. Of the barcodes identified in the stock, at least 85.6% actively replicated in at least one animal, and on average each barcode was found in 5 monkeys. Four infected animals were treated with combination antiretroviral therapy (cART) for 82 days starting on day 6 post-infection (study 1). Plasma viremia was reduced from >10(6) to <15 vRNA copies/mL by the time treatment was interrupted. Virus rapidly rebounded following treatment interruption and between 87 and 136 distinct clonotypes were detected in plasma at peak rebound viremia. This study confirmed that SIVmac239M viremia could be successfully curtailed with cART, and that upon cART discontinuation, rebounding viral variants could be identified and quantified. An additional 6 animals infected with SIVmac239M were treated with cART beginning on day 4 post-infection for 305, 374, or 482 days (study 2). Upon treatment interruption, between 4 and 8 distinct viral clonotypes were detected in each animal at peak rebound viremia. The relative proportions of the rebounding viral clonotypes, spanning a range of 5 logs, were largely preserved over time for each animal. The viral growth rate during recrudescence and the relative abundance of each rebounding clonotype were used to estimate the average frequency of reactivation per animal. Using these parameters, reactivation frequencies were calculated and ranged from 0.33–0.70 events per day, likely representing reactivation from long-lived latently infected cells. The use of SIVmac239M therefore provides a powerful tool to investigate SIV latency and the frequency of viral reactivation after treatment interruption. Public Library of Science 2017-05-04 /pmc/articles/PMC5433785/ /pubmed/28472156 http://dx.doi.org/10.1371/journal.ppat.1006359 Text en © 2017 Fennessey et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Fennessey, Christine M.
Pinkevych, Mykola
Immonen, Taina T.
Reynaldi, Arnold
Venturi, Vanessa
Nadella, Priyanka
Reid, Carolyn
Newman, Laura
Lipkey, Leslie
Oswald, Kelli
Bosche, William J.
Trivett, Matthew T.
Ohlen, Claes
Ott, David E.
Estes, Jacob D.
Del Prete, Gregory Q.
Lifson, Jeffrey D.
Davenport, Miles P.
Keele, Brandon F.
Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy
title Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy
title_full Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy
title_fullStr Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy
title_full_unstemmed Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy
title_short Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy
title_sort genetically-barcoded siv facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433785/
https://www.ncbi.nlm.nih.gov/pubmed/28472156
http://dx.doi.org/10.1371/journal.ppat.1006359
work_keys_str_mv AT fennesseychristinem geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT pinkevychmykola geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT immonentainat geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT reynaldiarnold geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT venturivanessa geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT nadellapriyanka geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT reidcarolyn geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT newmanlaura geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT lipkeyleslie geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT oswaldkelli geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT boschewilliamj geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT trivettmatthewt geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT ohlenclaes geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT ottdavide geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT estesjacobd geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT delpretegregoryq geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT lifsonjeffreyd geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT davenportmilesp geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy
AT keelebrandonf geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy